MedTrace Logo

Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers

NCT06837116 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-01-16

Study results available
· View outcomes & findings →

Summary

Official title: Immunogenicity of an intradermal Qdenga vaccine among healthy volunteers: A pilot study

Conditions

  • Dengue

Interventions

BIOLOGICAL

Vaccine

Subcutaneous route vs Intradermal route

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-19
Primary Completion
2025-08-30
Completion
2025-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06837116 on ClinicalTrials.gov